A systematic review of the efficacy of bioactive compounds in cardiovascular disease: Carbohydrates, active lipids and nitrogen compounds

Annals of Nutrition and Metabolism

Volumn 66, Issue 2-3, 2015, Pages 168-181

  Pastor Villaescusa, Belen ^a   Rangel Huerta, Oscar D ^a   Aguilera, Concepcion M ^a   Gil, Angel ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Bioactive food compounds; Carbohydrates; Cardiovascular diseases; Fatty acids; Nitrogen compounds

Indexed keywords

BETA GLUCAN; BIOLOGICAL MARKER; CARBOHYDRATE; CONJUGATED LINOLENIC ACID; DITERPENE; ESCIN; KAURANE DERIVATIVE; LINOLENIC ACID; LIPID; NITROGEN DERIVATIVE; NOBORNANE DERIVATIVE; PHYTOSTEROL; PLACEBO; TERPENE; TRIACYLGLYCEROL; TRITERPENE; UNCLASSIFIED DRUG; CARBOHYDRATE DIET; FLAVONOID; PLANT MEDICINAL PRODUCT; POLYSACCHARIDE; SULFUR DERIVATIVE;

ALLIUM; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; HOMEOSTASIS; HUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADMINISTRATION AND DOSAGE; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASES; DIET; DIETARY FIBER; MEDLINE;

AESCULUS; ALLIUM;

BETA-GLUCANS; CARDIOVASCULAR DISEASES; DIET; DIETARY CARBOHYDRATES; DIETARY FIBER; FLAVONOIDS; HUMANS; MEDLINE; NITROGEN COMPOUNDS; PHYTOCHEMICALS; PHYTOSTEROLS; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFUR COMPOUNDS;

EID: 84930526846     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000430960     Document Type: Review

References (63)

1. Martínez-Augustin O, Aguilera CM, Gil-Campos M, Sánchez de Medina F, Gil A: Bioactive anti-obesity food components. Int J Vitam Nutr Res 2012; 82: 148-156.
2. World Health Organization: Obesity and Overweight, 2015.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-1701.
4. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014; 63: 2889-2934.
5. Kitts DD: Bioactive substances in food: identification and potential uses. Can J Physiol Pharmacol 1994; 72: 423-434.
6. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, et al: Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 2002; 113(suppl 9B):71S-88S.
7. Food and Drug Administration: FDA Basics - Dietary Supplements, 2010.
8. Cugnet-Anceau C, Nazare JA, Biorklund M, Le Coquil E, Sassolas A, Sothier M, et al: A controlled study of consumption of beta-glucan-enriched soups for 2 months by type 2 diabetic free-living subjects. Br J Nutr 2010; 103: 422-428.
9. Chinnadurai K, Kanwal HK, Tyagi AK, Stanton C, Ross P: High conjugated linoleic acid enriched ghee (clarified butter) increases the antioxidant and antiatherogenic potency in female Wistar rats. Lipids Health Dis 2013; 12: 121.
10. Crowell PL: Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999; 129: 775S-778S.
11. Pittler MH, Ernst E: Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2012; 11:CD003230.
12. Law MR: Plant sterol and stanol margarines and health. West J Med 2000; 173: 43-47.
13. Thompson GR, Grundy SM: History and development of plant sterol and stanol esters for cholesterol-lowering purposes. Am J Cardiol 2005; 96: 3-9.
14. Rahman K, Lowe GM: Garlic and cardiovascular disease: a critical review. J Nutr 2006; 136(3 suppl):736S-740S.
15. Scottish Intercollegiate Guidelines Network: Risk Estimation and the Prevention of Cardiovascular Disease: A National Clinical Guideline (97), 2007. http://www.sign.ac.uk/ pdf/sign97.pdf.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
17. Uauy R: Fats and Fatty Acids in Human Nutrition: Report of An Expert Consultation. FAO Food and Nutrition Paper, 2008, vol 550, p 189.
18. Maki KC, Galant R, Samuel P, Tesser J, Witchger MS, Ribaya-Mercado JD, et al: Effects of consuming foods containing oat betaglucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. Eur J Clin Nutr 2007; 61: 786-795.
19. Keogh GF, Cooper GJ, Mulvey TB, McArdle BH, Coles GD, Monro JA, et al: Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. Am J Clin Nutr 2003; 78: 711-718.
20. Raff M, Tholstrup T, Basu S, Nonboe P, Sorensen MT, Straarup EM: A diet rich in conjugated linoleic acid and butter increases lipid peroxidation but does not affect atherosclerotic, inflammatory, or diabetic risk markers in healthy young men. J Nutr 2008; 138: 509-514.
21. Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP: Conjugated linoleic acid impairs endothelial function. Arterioscler Thromb Vasc Biol 2006; 26: 307-312.
22. Naumann E, Carpentier YA, Saebo A, Lassel TS, Chardigny JM, Sébédio JL, et al: Cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid (CLA) do not affect the plasma lipoprotein profile in moderately overweight subjects with LDL phenotype B. Atherosclerosis 2006; 188: 167-174.
23. Aryaeian N, Shahram F, Djalali M, Eshragian MR, Djazayeri A, Sarrafnejad A, et al: Effect of conjugated linoleic acid, vitamin E and their combination on lipid profiles and blood pressure of Iranian adults with active rheumatoid arthritis. Vasc Health Risk Manag 2008; 4: 1423-1432.
24. Kroll M, Ring C, Gaus W, Hempel B: A randomized trial of Korodin Herz-Kreislauf-Tropfen as add-on treatment in older patients with orthostatic hypotension. Phytomedicine 2005; 12: 395-402.
25. Schandry R, Duschek S: The effect of Camphor-Crataegus berry extract combination on blood pressure and mental functions in chronic hypotension - a randomized placebo controlled double blind design. Phytomedicine 2008; 15: 914-922.
26. Belz GG, Butzer R, Gaus W, Loew D: Camphor-Crataegus berry extract combination dose-dependently reduces tilt induced fall in blood pressure in orthostatic hypotension. Phytomedicine 2002; 9: 581-588.
27. Ferri LA, Alves-Do-Prado W, Yamada SS, Gazola S, Batista MR, Bazotte RB: Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. Phytother Res 2006; 20: 732-736.
28. Hsieh MH, Chan P, Sue YM, Liu JC, Liang TH, Huang TY, et al: Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study. Clin Ther 2003; 25: 2797-2808.
29. Chan P, Tomlinson B, Chen YJ, Liu JC, Hsieh MH, Cheng JT: A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. Br J Clin Pharmacol 2000; 50: 215-220.
30. Barriocanal LA, Palacios M, Benitez G, Benitez S, Jimenez JT, Jimenez N, et al: Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regul Toxicol Pharmacol 2008; 51: 37-41.
31. Ottillinger B, Greeske K: Rational therapy of chronic venous insufficiency - chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovasc Disord 2001; 1: 5.
32. Allen RR, Carson L, Kwik-Uribe C, Evans EM, Erdman JW Jr: Daily consumption of a dark chocolate containing flavanols and added sterol esters affects cardiovascular risk factors in a normotensive population with elevated cholesterol. J Nutr 2008; 138: 725-731.
33. Earnest CP, Mikus CR, Lemieux I, Arsenault BJ, Church TS: Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease. Nutrition 2007; 23: 625-633.
34. Lane JD, Pieper CF, Phillips-Bute BG, Bryant JE, Kuhn CM: Caffeine affects cardiovascular and neuroendocrine activation at work and home. Psychosom Med 2002; 64: 595-603.
35. Shechter M, Shalmon G, Scheinowitz M, Koren-Morag N, Feinberg MS, Harats D, et al: Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease. Am J Cardiol 2011; 107: 1255-1261.
36. Duffy SJ, Keaney JF Jr, Holbrook M, Gokce N, Swerdloff PL, Frei B, et al: Short- and longterm black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001; 104: 151-156.
37. Steiner M, Li W: Aged garlic extract, a modulator of cardiovascular risk factors: a dosefinding study on the effects of AGE on platelet functions. J Nutr 2001; 131: 980S-984S.
38. Budoff MJ, Takasu J, Flores FR, Niihara Y, Lu B, Lau BH, et al: Inhibiting progression of coronary calcification using aged garlic extract in patients receiving statin therapy: a preliminary study. Prev Med 2004; 39: 985-991.
39. Sobenin IA, Pryanishnikov VV, Kunnova LM, Rabinovich YA, Martirosyan DM, Orekhov AN: The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis 2010; 9: 119.
40. Williams MJ, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA: Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res 2005; 19: 314-319.
41. Ried K, Frank OR, Stocks NP: Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial. Eur J Clin Nutr 2013; 67: 64-70.
42. Ried K, Frank OR, Stocks NP: Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Maturitas 2010; 67: 144-150.
43. Sobenin IA, Andrianova IV, Fomchenkov IV, Gorchakova TV, Orekhov AN: Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension. Hypertens Res 2009; 32: 433-437.
44. Liu Y, Zhang L, Liu YF, Yan FF, Zhao YX: Effects of Bulbus allii macrostemi on clinical outcomes and oxidized low-density lipoprotein and plasminogen in unstable angina/ non-ST-segment elevation myocardial infarction patients. Phytother Res 2008; 22: 1539-1543.
45. Jenkins AL, Jenkins DJ, Zdravkovic U, Würsch P, Vuksan V: Depression of the glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. Eur J Clin Nutr 2002; 56: 622-628.
46. Chen J, Raymond K: Beta-glucans in the treatment of diabetes and associated cardiovascular risks. Vasc Health Risk Manag 2008; 4: 1265-1272.
47. Brouwer IA, Wanders AJ, Katan MB: Trans fatty acids and cardiovascular health: research completed? Eur J Clin Nutr 2013; 67: 541-547.
48. Aminot-Gilchrist DV, Anderson HD: Insulin resistance-associated cardiovascular disease: potential benefits of conjugated linoleic acid. Am J Clin Nutr 2004; 79(6 suppl):1159S-1163S.
49. Tirapelli CR, Ambrosio SR, da Costa FB, Coutinho ST, de Oliveira DC, de Oliveira AM: Analysis of the mechanisms underlying the vasorelaxant action of kaurenoic acid in the isolated rat aorta. Eur J Pharmacol 2004; 492: 233-241.
50. Tirapelli CR, Ambrosio SR, de Oliveira AM, Tostes RC: Hypotensive action of naturally occurring diterpenes: a therapeutic promise for the treatment of hypertension. Fitoterapia 2010; 81: 690-702.
51. Hipólito UV, Rodrigues GJ, Lunardi CN, Bonaventura D, Ambrosio SR, de Oliveira AM, et al: Mechanisms underlying the vasorelaxant action of the pimarane ent-8(14),15-pimaradien-3beta-ol in the isolated rat aorta. Eur J Pharmacol 2009; 616: 183-191.
52. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G: Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005; 25: 171-183.
53. Genser B, Silbernagel G, De Backer G, Bruckert E, Carmena R, Chapman MJ, et al: Plant sterols and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2012; 33: 444-451.
54. Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM: Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 2005; 23: 921-928.
55. Mostofsky E, Rice MS, Levitan EB, Mittleman MA: Habitual coffee consumption and risk of heart failure: a dose-response meta-analysis. Circ Heart Fail 2012; 5: 401-405.
56. Kim-Park S, Ku DD: Garlic elicits a nitric oxide-dependent relaxation and inhibits hypoxic pulmonary vasoconstriction in rats. Clin Exp Pharmacol Physiol 2000; 27: 780-786.
57. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T: Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2008; 8: 13.
58. Reinhart KM, Coleman CI, Teevan C, Vachhani P, White CM: Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann Pharmacother 2008; 42: 1766-1771.
59. Stabler SN, Tejani AM, Huynh F, Fowkes C: Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients. Cochrane Database Syst Rev 2012; 8:CD007653.
60. Simons S, Wollersheim H, Thien T: A systematic review on the influence of trial quality on the effect of garlic on blood pressure. Neth J Med 2009; 67: 212-219.
61. Budoff MJ, Ahmadi N, Gul KM, Liu ST, Flores FR, Tiano J, et al: Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. Prev Med 2009; 49: 101-107.
62. Zeng T, Guo FF, Zhang CL, Song FY, Zhao XL, Xie KQ: A meta-analysis of randomized, double-blind, placebo-controlled trials for the effects of garlic on serum lipid profiles. J Sci Food Agric 2012; 92: 1892-1902.
63. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al: Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on cardiac imaging, council on clinical cardiology. Circulation 2006; 114: 1761-1791.